Mark Quigley Net Worth

The estimated Net Worth of Mark Quigley is at least $443 Thousand dollars as of 12 May 2015. Mark Quigley owns over 18,750 units of Insmed Inc stock worth over $443,399 and over the last 10 years Mark sold INSM stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mark Quigley INSM stock SEC Form 4 insiders trading

Mark has made over 1 trades of the Insmed Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Mark exercised 18,750 units of INSM stock worth $292,688 on 12 May 2015.

The largest trade Mark's ever made was exercising 18,750 units of Insmed Inc stock on 12 May 2015 worth over $292,688. On average, Mark trades about 6,250 units every 0 days since 2014. As of 12 May 2015 Mark still owns at least 6,094 units of Insmed Inc stock.

You can see the complete history of Mark Quigley stock trades at the bottom of the page.

What's Mark Quigley's mailing address?

Mark's mailing address filed with the SEC is 9 DEER PARK DRIVE, , MONMOUTH JUNCTION, NJ, 08852.

Insiders trading at Insmed Inc

Over the last 22 years, insiders at Insmed Inc have traded over $46,121,705 worth of Insmed Inc stock and bought 1,080,212 units worth $8,226,993 . The most active insiders traders include Llc Fmr, William Lewis, and Dennis M Lanfear. On average, Insmed Inc executives and independent directors trade stock every 38 days with the average trade being worth of $2,452,158. The most recent stock trade was executed by Orlov S Nicole Schaeffer on 10 September 2024, trading 37,575 units of INSM stock currently worth $407,689.

What does Insmed Inc do?

insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. the company is dedicated to developing and bringing to market therapies that make a real difference in patients’ lives, while striving to understand and enhance the entire patient experience, from diagnosis and treatment to everyday living. headquartered in bridgewater, nj, we are a rapidly growing company with offices in seven countries.

Complete history of Mark Quigley stock trades at Insmed Inc

Insmed Inc executives and stock owners

Insmed Inc executives and other stock owners filed with the SEC include:

• William Lewis,
  Chairman of the Board, President, Chief Executive Officer
• Roger Adsett,
  Chief Operating Officer
• Christine Pellizzari,
  Chief Legal Officer
• S. Nicole Schaeffer,
  Chief People Strategy Officer
• William H. Lewis J.D., M.B.A.,
  Pres, CEO & Chairman
• Dr. Martina Flammer M.B.A., M.D.,
  Chief Medical Officer
• John Goll,
  Chief Accounting Officer
• Roger Adsett,
  Chief Operating Officer
• Christine A. Pellizzari J.D.,
  Consultant
• Sara M. Bonstein MBA,
  Chief Financial Officer
• John Goll III,
  Sr. VP & Chief Accounting Officer
• David Brennan,
  Lead Independent Director
• Alfred Altomari,
  Independent Director
• Steinar Engelsen,
  Independent Director
• David McGirr,
  Independent Director
• Melvin Sharoky,
  Independent Director
• Leo Lee,
  Independent Director
• Elizabeth Anderson,
  Independent Director
• Clarissa Desjardins,
  Independent Director
• Carol Schafer,
  Director
• Martina Flammer,
  Chief Medical Officer
• John Soriano,
  Chief Compliance Officer
• Sara Bonstein,
  Chief Financial Officer
• S. Nicole Schaeffer,
  Chief People Strategy Officer
• Mandy Fahey,
  Sr. Director of Corp. Communications
• Michael Alexander Smith,
  Sr. VP & Gen. Counsel
• John D. Soriano J.D.,
  Chief Compliance Officer
• Eleanor Barisser,
  Associate Director of Investor Relations
• Paolo Tombesi,
  Chief Financial Officer
• Paul Streck,
  Chief Medical Officer
• Eugene Jeffrey Sullivan,
  Chief Medical Officer
• Myrtle S Potter,
  Director
• Donald J Jr Hayden,
  Director
• Geoffrey Allan,
  President, CEO and Chairman
• Stephen C. Glover,
  President Follow-on Biologics
• Doug Farrar,
  Vice President, ITP
• Michael Duncan,
  Principal Financial Officer
• Thomas A Keuer,
  VP, ITP (Subsidiary)
• Philip J Young,
  Chief Business Officer and EVP
• Ronald D Gunn,
  Executive Vice President
• Mark Quigley,
  Vice President, Quality
• Randall W Whitcomb,
  Director
• Peggy Berry,
  Vice President, Regulatory
• Renu Gupta,
  Chief Medical Officer
• Richard S Kollender,
  Director
• Matthew Pauls,
  Chief Commercial Officer
• Llc Fmr,
  10% owner
• Andrea Holtzman Drucker,
  Senior V.P., General Counsel
• Nicholas A. Jr. La Bella,
  Chief Scientific Officer
• Kenneth G Condon,
  Director
• Kevin P Tully,
  Executive VP & CFO
• Timothy Whitten,
  President & CEO
• Graham K Crooke,
  Director
• Nicholas Lee Gurreri,
  Senior VP, Commercial Ops
• Dennis M Lanfear,
  Director
• John Drayton Wise,
  Chief Commercial Officer
• Michael Alexander Smith,
  Chief Legal Officer